Clinical Trial

12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence

Study acronym: MEDSEC-CTA12
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Current scientific evidence demonstrates the relationship between good physical fitness and a lower incidence of certain chronic diseases, including smoking, as well as the effectiveness of cytisinicline. This protocol aims to evaluate the efficacy of the synergistic effect of combining structured physical exercise, brief counseling, and cytisinicline administration in achieving smoking cessation. The study will be an experimental, multicenter, randomized, and controlled trial with two parallel arms, conducted by a multidisciplinary team within the primary care setting of the Andalusian public health system, with a 12-month follow-up. The estimated sample size is 75 participants per arm. One of the study arms will include a structured exercise program aligned with the recently approved regional Andalusian health plan.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-29.
Trial Details
NCT Number NCT06579846
Lead Sponsor Maimónides Biomedical Research Institute of Córdoba
Collaborators: Universidad de Córdoba
Conditions Smoking Cessation
Enrollment 150 participants
Start Date 2025-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-04